why choose us

First received: August 19, 2022

Clinical Trial: Plerixafor for Poorly Mobilized Lymphoma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Lymphoma

Study Type: INTERVENTIONAL


Official Title: Efficacy and Safety of Plerixafor in Patients With Poorly Mobilized Lymphoma

Brief Summary: Autologous hematopoietic stem cell transplantation is one of the effective means of lymphoma treatment, but patients who receive transplantation in the absence of sufficient stem cell numbers have a delay in stem cell engraftment and a markedly increased risk of infection and emergence.Plerixafor injection is a strong and specific antagonist of CXCR4.It can rapidly mobilize stem cells from bone marrow into peripheral blood circulation by blocking the combination of SDF1 and CXCR4.Studies have shown that the…

Read more